BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34320363)

  • 1. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.
    Dai C; Rennhack JP; Arnoff TE; Thaker M; Younger ST; Doench JG; Huang AY; Yang A; Aguirre AJ; Wang B; Mun E; O'Connell JT; Huang Y; Labella K; Talamas JA; Li J; Ilic N; Hwang J; Hong AL; Giacomelli AO; Gjoerup O; Root DE; Hahn WC
    Cell Rep; 2021 Jul; 36(4):109443. PubMed ID: 34320363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
    Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
    Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.
    Leung L; Radulovich N; Zhu CQ; Wang D; To C; Ibrahimov E; Tsao MS
    PLoS One; 2013; 8(12):e84366. PubMed ID: 24386371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
    Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
    Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
    Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
    Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer.
    Hurwitz E; Parajuli P; Ozkan S; Prunier C; Nguyen TL; Campbell D; Friend C; Bryan AA; Lu TX; Smith SC; Razzaque MS; Xu K; Atfi A
    J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36828547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
    Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
    Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
    Sunamura M; Lefter LP; Duda DG; Morita R; Inoue H; Yokoyama T; Yatsuoka T; Abe T; Egawa S; Furukawa T; Fukushige S; Oshimura M; Horii A; Matsuno S
    Pancreas; 2004 Apr; 28(3):311-6. PubMed ID: 15084978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX3 Modulates Metastatic Potential in Pancreatic Ductal Adenocarcinoma.
    Cancer Discov; 2015 Jul; 5(7):OF27. PubMed ID: 26045017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
    Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
    Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.
    Fullerton PT; Creighton CJ; Matzuk MM
    Mol Endocrinol; 2015 Oct; 29(10):1440-53. PubMed ID: 26284758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.
    Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M
    Oncogene; 2013 Aug; 32(33):3867-76. PubMed ID: 22945649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically relevant model of human pancreatic adenocarcinoma identifies patterns of metastasis associated with alterations of the TGF-beta/Smad4 signaling pathway.
    Holloway S; Davis M; Jaber R; Fleming J
    Int J Gastrointest Cancer; 2003; 33(1):61-9. PubMed ID: 12909738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
    Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
    PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma.
    Guo J; Kleeff J; Zhao Y; Li J; Giese T; Esposito I; Büchler MW; Korc M; Friess H
    Int J Mol Med; 2006 May; 17(5):761-7. PubMed ID: 16596258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.
    Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH
    Mol Cancer Res; 2013 Jul; 11(7):768-79. PubMed ID: 23552743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.